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Background: The primary glioblastoma multiforme (GBM) is the most malignant form of astrocytic tumor with an
average survival of approximately 12–14 months. The search for novel and more efficient chemo-agents against this
disease is urgent. Salinomycin induces broad anti-cancer effects; however, its role in GBM and the underlying
mechanism are not clear.
Results: Here we found that salinomycin induced both apoptosis and necrosis in cultured glioma cells, and
necrosis played a major role in contributing salinomycin’s cytotoxicity. Salinomycin induced p53 translocation
to mitochondria, where it formed a complex with cyclophilin-D (CyPD). This complexation was required for
mitochondrial permeability transition pore (mPTP) opening and subsequent programmed necrosis. Blockade of
Cyp-D by siRNA-mediated depletion or pharmacological inhibitors (cyclosporin A and sanglifehrin A) significantly
suppressed salinomycin-induced glioma cell necrosis. Meanwhile, p53 stable knockdown alleviated salinomycin-induced
necrosis in glioma cells. Reactive oxygen species (ROS) production was required for salinomycin-induced p53
mitochondrial translocation, mPTP opening and necrosis, and anti-oxidants n-acetylcysteine (NAC) and pyrrolidine
dithiocarbamate (PDTC) inhibited p53 translocation, mPTP opening and glioma cell death.
Conclusions: Thus, salinomycin mainly induces programmed necrosis in cultured glioma cells.
Keywords: Salinomycin, Glioma, Programmed necrosis, Mitochondrial permeability transition pore (mPTP),
Cyclophilin-D and p53Background
The primary glioblastoma multiforme (GBM) is the
most malignant form of astrocytic tumor, which has one
of the worst prognoses among all human tumors, with a
median survival of approximately 12 months [1–7]. In
the past three decades, postoperative radiation and/or
temozolomide (TMZ) become the current standard care
for GBM [1, 3, 4]. However, there has been no signifi-
cant improvement in the overall survival [1, 3, 4]. One
key hurdle is the molecular heterogeneity of GBM,
which impedes uniform application of specific molecu-
larly targeted agents [2]. Thus, the search for novel and
more efficient chemo-agents against this deadly disease
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creativecommons.org/publicdomain/zero/1.0/The results of a recent high-throughput screening
study indentified that salinomycin, an antibacterial and
coccidiostat ionophore therapeutic drug, selectively kills
cancer stem cells from tumorspheres, and inhibits tumor
growth in mice [8]. Since then, a number of groups have
studied salinomycin as a potential anti-cancer agent [8,
9], and results have shown that salinomycin inhibits the
growth of various immortalized cancer cells both in vivo
and in vitro [10–13]. However, the underlying mecha-
nisms are not fully understood, although Wnt suppres-
sion [11], p-glycoprotein inhibition [9] and reactive
oxygen species (ROS) production [12] have been associ-
ated with salinomycin-mediated anti-cancer effects. In
the current study, we investigated the potential role of
salinomycin in glioma cells, and studied the molecular
mechanisms involved.
It has been long believed that necrotic cell death is a
passive and uncontrolled form of cell death. Recently,
however, it is discovered that necrosis, similar to apop-
tosis, is also a molecularly regulated event that isle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Further studies have found that mitochondrial perme-
ability transition pore (mPTP), the mitochondrial chan-
nel complex, plays a vital role in mediating this
“programmed necrosis” [17–20]. MPTP is composed of
at least three primary components, including the
voltage-dependent anion channel (VDAC), the adenine
nucleotide translocator-1 (ANT-1) and the mitochon-
drial matrix protein cyclophilin D (Cyp-D) [17, 20, 21].
Cyp-D is known to sit in the mitochondrial matrix to
keep the mPTP closed [20–22]. Under stress conditions,
i.e. Ca2+ [14, 23], hypoxia [14, 23], ROS [24], UV radi-
ation [25], Cyp-D will associate with ANT-1 in the inner
membrane, open the mPTP pore, cause mitochondrial
membrane potential (MMP) loss, mitochondria swelling,
Ca2+ release, ROS production, and eventually leading to
cell necrosis. Interestingly, recent studies have impli-
cated the important role of Cyp-D dependent mPTP
opening in certain chemo-drugs-induced cancer cell
necrosis [26, 27]. In the current study, we found that sal-




Salinomycin, sanglifehrin A (SfA), cyclosporine A (CsA),
n-acetyl cysteine (NAC), temozolomide (TMZ) and pyr-
rolidinedithiocarbamate (PDTC) were purchased from
Sigma (St. Louis, MO). Necrostatin-1 (Nec-1) was pur-
chased from Cayman Chemical (Beijing, China). Anti-
bodies against tubulin and Cyp-D were purchased from
Santa Cruz Biotech (Santa Cruz, CA), antibodies for p53
(regular and specific sites of phosphorylation) were pur-
chased from Cell Signaling Technology (Danvers, MA).
Cell culture
U87MG, U251MG and EFC-2 glioma cells were main-
tained in dulbecco’s modified Eagle’s medium (DMEM,
Sigma, St. Louis, MO), supplemented with a 10 % fetal
bovine serum (FBS, Sigma), penicillin/streptomycin (1:100;
Sigma) and in a CO2 incubator at 37 °C.
Primary culture of mouse astrocytes
Tissues from whole brains of post-natal (P1–P2) mice
were triturated, and then cells were placed on poly-d-
lysine pre-coated cell culture flasks in DMEM contain-
ing 15 % FBS, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Cultures were maintained at 37 °C in a
humidified atmosphere of 5 % CO2/95 % filtered air.
After reaching a confluent monolayer of glial cells (10–
14 days), microglia were separated from astrocytes by
shaking off for 5 h at 100 rpm. The enriched astrocytes
were >96 % positive for glial fibrillary acidic protein
(GFAP).Cell viability MTT assay
The cell viability was measured by the 3-[4,5-
dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium bromide
(MTT) (Sigma, St. Louis, MO) method as reported [28].
Briefly, cells were seeded in 96-well plates with 70–80 %
confluence. After indicated treatment/s, MTT tetrazolium
salt (0.25 mg/ml) was added to each well for 2 h at 37 °C.
Afterwards, 200 μl of DMSO was added to dissolve forma-
zan crystals. The absorbance of each well was observed by
a plate reader at a test wavelength of 490 nm. The value of
each treatment group was expressed as percentage change
of that of control group.
“Dead” cell detection by trypan blue staining
As reported [28], the number of dead glioma cells
(trypan blue positive) after treatment was recorded,
and the percentage (%) of dead cells was calculated
by the number of the trypan blue stained cells di-
vided by the total cell number, which was automatically
tested by a handheld automated cell counter (Merck
Millipore, Shanghai, China).
Clonogenicity assay
As reported [28], U87MG cells (5× 103) were suspended
in 1 ml of DMEM containing 0.1 % agar (Sigma, St.
Louis, MO), 10 % FBS and with indicated treatments or
the vehicle control. The cell suspension was then added
on top of a pre-solidified 100 mm culture dish. The
medium was replaced every two days. After 10 days of
incubation, colonies were photographed at 4×. The
number of large colonies (>50 μm in diameter) was
manually counted and recorded, and the number was
expressed as percentage change of the control group.
Analysis cell apoptosis and necrosis by fluorescence-
activated cell sorting (FACS) sorting propidium
iodide (PI) -Annexin V staining
As reported [28], the glioma cell apoptosis and necrosis
were determined by the Annexin V In Situ Cell
Apoptosis Detection Kit (Roche Molecular Biochemicals,
Indianapolis, IN, USA) according to the manufacturer’s
protocols. Briefly, after indicated treatment/s, glioma cells
were stained with Annexin V and propidium iodide (PI)
(Molecular Probes). The cell apoptosis percentage was
reflected by Annexin V+/+/PI−/− plus Annexin V+/+/PI+/+
percentage detected by fluorescence-activated cell sorting
(FACS) (BD, Shanghai, China). Annexin V−/−/PI+/+ per-
centage was utilized as an indicator of cell necrosis. The
time point for FACS assay was selected based on pre-
experiment results.
Caspase-3 activity assay
The cytosol proteins of approximately 2 × 106 glioma
cells were extracted in cell lysis buffer containing 25 mm
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and 0.05 % phenylmethylsulfonyl fluoride, (pH 7.5).
Twenty μg of cytosolic extracts were added to caspase
assay buffer (312.5 mM HEPES, pH 7.5, 31.25 % su-
crose, 0.3125 % CHAPS) with benzyloxycarbonyl-
DEVD-7-amido-4-(trifluoromethyl)-coumarin as substrate
(Calbiochem, Darmstadt, Germany). After 2 h of incuba-
tion at 37 °C, the release of 7-amido-4-(trifluoromethyl)
coumarin (AFC) was quantified, using a Fluoroskan sys-
tem set to an excitation value of 355 nm and emission
value of 525 nm. The value of each result was normal-
ized, and was expressed as fold change vs. that of ve-
hicle control group.
Protein isolation and Western blots
Cells were washed with ice-cold PBS and then lysed using
lysis buffer containing 1 % Nonidet P-40, 1 % deoxycholate,
0.1 % sodium dodecyl sulfate, 150 mmol/L sodium chloride
and 10 mmol/L Tris–HCl (pH, 7.4). The lysates were col-
lected and centrifuged. The concentration of the extracted
protein was measured by bicinchoninic acid assay kit
(Sigma). The extracted protein was boiled for 5 min in
loading buffer. Samples were separated on 10 % SDS-
polycrylamide gel, and after electro-blotting onto polyviny-
lidene fluoride (PVDF) membranes (Millipore, Shanghai,
China), the membranes were blocked with blocking solu-
tion [10 % (w/v) milk in Tris-buffered solution plus
Tween-20 (TBST), incubated overnight at 4 °C with pri-
mary antibodies, and then incubated with HRP-conjugated
anti-rabbit/mouse second antibodies. The detection
was performed by Super-signal West Pico Enhanced
Chemiluminescent (ECL) Substrate according to the man-
ufacturer’s protocol. The blot intensity was quantified and
normalized as previously reported [28]. For detecting pro-
teins in the mitochondria, intact mitochondria of cultured
2.0 × 107 glioma cells were isolated using the “Mitochondria
Isolation Kit for Cultured Cells” (Pierce, Rockford, IL).
Immuno-precipitation (IP)
After treatment, 600 μg of cell lysates from mitochon-
drial fractions of glioma cells were pre-cleared. The
supernatant was then rotated overnight with 2 μg of
anti-Cyp-D (Santa Cruz Biotech). Next, the lysates were
centrifuged for 5 min at 4 °C in a micro-centrifuge to
remove nonspecific aggregates. The protein A/G PLUS-
agarose (35 μl, Sigma) was then added to the superna-
tants for 4 h at 4 °C. Pellets were washed six times with
PBS, resuspended in lysis buffer, and then assayed by
Western blots. The time point for IP was based on pre-
vious publications and results from pre-experiments.
Cyp-D siRNA
The SiRNA duplexes against human cyclophilin-D were
purchased from Santa Cruz. LipofectamineTM 2000 wasapplied to transfect RNAi (100 nM) into cultured glioma
cells according to manufacturer’s protocol. The same
amount of scramble non-sense siRNA (control siRNA,
Santa Cruz) was transfected into control cells. After
48 h, the Cyp-D expression and the equal loading in
transfected cells were examined by Western blots. Only
successfully transfected cells, demonstrated by markedly
reduced level of Cyp-D, were used for further experi-
ments. The transfection was repeated one more round if
necessary.
Detection of mitochondrial membrane potential (MMP)
Similar to previous reported, the MMP of glioma cells
was measured through JC-10 dye (Invitrogen, Carlsbad,
CA) [29]. The JC-10 dye exhibits two staining spectra.
In normally resting cells, the dye forms aggregates in the
mitochondrial membrane, exhibiting orange fluores-
cence. When the membrane potential is decreasing, the
monomeric JC-10 will form in the cytosol, exhibiting the
green fluorescence. Thus, the intensity of green fluores-
cence can be used as indicator of MMP loss. Briefly,
after treatment, glioma cells were stained with 5.0 μg/ml
of JC-10 for 5 min at room temperature under dark.
Cells were then washed twice with warm PBS, and re-
suspended in fresh culture medium and read immedi-
ately on a microplate reader with an excitation filter of
485 nm. The OD value was used as an indicator of
MMP loss.
Cyp-D vector and transfection
The wt-Cyp-D plasmid (pSuper-puromycin-GFP- Cyp-
D) and the empty vector (pSuper-puromycin) were gifts
from Dr. Wang [29]. LipofectamineTM and PLUS reagent
(Invitrogen, Carlsbad, CA) were applied to transfect
Cyp-D plasmid or the vector (1 μg/ml) into cells accord-
ing the manufacturer’s protocol. The stable clones
were selected by puromycin (0.25 μg/ml medium). The
puromycin-containing medium was refreshed every 3 days,
until single resistant colony can be formed (4 weeks). The
Cyp-D expression in the stable clones was always detected
by Western blots to confirm the transfection efficiency.
Only colonies with over-expressed Cyp-D were utilized for
experiments.
P53 shRNA knockdown and stable cell selection
P53 shRNA containing lentiviral particles were added to
cultured glioma cells at the dose of 20 μl/ml medium,
the infection took 48 h, afterwards, puromycin (0.25 μg/ml)
was added to select the stable clones. The puromycin-
containing medium was refreshed every 3 days, until
single resistant colony can be formed (4 weeks). P53
expression in the stable colony was always detected
by Western blots to confirm the infection efficiency.
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of scramble shRNA containing lentiviral particles.
Reactive oxygen species (ROS) detection
Intracellular ROS generation was measured by flow
cytometry using dichlorofluorescin (DCF) oxidation
assay [30]. DCFH-DA enters passively into cells and
is cleaved by nonspecific cellular esterase and oxi-
dized in the presence of ROS. Briefly, 3*105 glioma
cells were plated in 60-mm culture plates overnight.
After treatment, cells were incubated with DCFH-DA
(5 μM) for 1 h at 37 °C. Thereafter, cells were washed
with PBS and kept in 1 ml PBS, ROS fluorescence was
analyzed using flow cytometer. The value of treatment
group was expressed as fold change to that of untreated
control group.
The superoxide dismutase (SOD) activity assay
The SOD activity was measured using a SOD activity
assay kit (BioVision, Mountain View, CA) according to
the manufacturer’s protocol. Briefly, cells were seeded
onto 100-mm2 dishes at a density of 5 × 106 cells/dish.
After treatment, the cells were washed with PBS, scraped
from the plates into 1 mL of ice-cold PBS (containing
0.05 mM of EDTA), and homogenized. The homogenate
was centrifuged at 4000 × g for 30 min at 4 °C. The
resulting supernatant (20 μl) was added with 200 μl of
water soluble tetrazolium working solution and 20 μL of
enzyme working solution to a 96-well plate. After incu-
bating the plate at 37 °C for 20 min, the absorbance at
450 nm was read using a microplate reader.
Xenograft assays
Nude mice were purchased from Suzhou University
Institute of Biological Science. U251 cells (106 cells in
100 μL of saline/Matrigel (BD Pharmigen San Jose, Ca),
1:1 v/v) were injected subcutaneously into the right flank
of 4-weeks-old female mice. Treatments were started
after tumor reached approximately 200 mm3 (around
4 weeks after inoculation). Salinomycin (5.0 mg/kg) or
with CsA (5.0 mg/kg) were administered to mice (10 per
group) once daily for two weeks, intraperitoneally. The
size of the tumors was measured by caliper every week,
and tumor volumes were calculated using the follow-
ing formula: π/6 × width 2× length. Control mice re-
ceived vehicle only with the same schedule. All animal
procedures were performed according to the Animal
Experimentation guidelines upon approval of the ex-
perimental protocol by Soochow University and Shanghai
Jiao Tong University. The study was approved by
Soochow University and Shanghai Jiao Tong University
review boards. All investigations were conducted accord-
ing to the principles expressed in the Declaration of
Helsinki.Statistical analysis
The data presented in this study were means ± standard
deviation (SD). Statistical differences were analyzed by
one-way ANOVA followed by multiple comparisons per-
formed with post hoc Bonferroni test (SPSS version 18).
Values of p < 0.05 were considered statistically signifi-
cant. The difference between two groups was tested
using paired-samples t test.
Results
Salinomycin inhibits proliferation and survival of cultured
glioma cells in vitro
We first tested the potential role of salinomycin in cul-
tured glioma cells. MTT cell viability assay results in
Fig. 1a demonstrated that salinomycin dose-dependently
inhibited U87MG cell survival. Meanwhile, the anti-
survival effect of salinomycin was time-dependent
(Fig. 1b). The viability of U87MG cells started to de-
crease 48 h after salinomycin (5 μM) treatment in
U87MG cells (Fig. 1b). Using the trypan blue staining
assay, we found that salinomycin treatment caused sig-
nificant cytotoxicity of U87MG cell death, and the effect
again was dose-dependently (Fig. 1c). To further confirm
the potential role of salinomycin on proliferation of
glioma cells, clonogenicity assay was performed, and re-
sults showed that salinomycin (5 μM) significantly re-
duced the number of survival colonies of U87MG cells
(Fig. 1d). Figure 1e demonstrated that salinomycin inhib-
ited the viability of U251MG and EFC-2 glioma cells.
We also tested the potential cytotoxicity of salinomycin
against primary cultured mouse astrocytes, and found
that salinomycin (5–10 μM) only slightly inhibited the
survival of primary astrocytes (Fig. 1f and g).
Together, these results show that salinomycin in-
hibits proliferation and survival of cultured glioma
cells in vitro.
Salinomycin mainly induces necrotic death of glioma cells
The results above confirmed the cytotoxic effect of sali-
nomycin in glioma cells; we then explored the role of
apoptosis and necrosis in it. By using two different as-
says including Annexin V-FACS assay and caspase-3 ac-
tivity assay, our results demonstrated that salinomycin
induced moderate cell apoptosis (less than 15 %) in
U87MG cells (Fig. 2a and b), which was blocked by the
apoptosis inhibitor zVADfmk (Fig. 2a and b). Meanwhile,
the Western blot results in Fig. 2c showed caspase-3
cleavage and cytochrome C release in salinomycin-
treated U87MG cells, further supporting apoptosis in-
duction. Note that less than 10 % cells were apoptotic
after 5 μM of salinomycin stimulation in U87MG cells
(Fig. 2a). Further, zVADfmk only slightly inhibited
salinomycin-induced viability reduction and cell death in
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Fig. 1 Salinomycin inhibits proliferation and survival of cultured glioma cells in vitro. U87MG glioma cells were treated with indicated concentration of
salinomycin (Sali) for 72 h, or treated with 5 μM of salinomycin (Sali) for indicated time, cell viability and cell death were analyzed by MTT assay (a and b)
and trypan blue staining (c) respectively. U87MG cells were cultured in salinomycin (Sali, 5 μM) containing medium for 10 days, and the left survival
colonies were counted, representative images were also shown (d). U251MG and EFC-2 glioma cells were treated with salinomycin (Sali, 5 μM) for 72 h;
cell viability was tested by MTT assay (e). Primary mouse astrocytes were treated with indicated concentration of salinomycin (Sali) for 72 h, cell
morphology and viability were shown in (f) and (g). Experiments were repeated four times in this figure, and similar results were obtained.
Error bars indicate standard deviation (SD). *p < 0.05 vs. untreated control (“c”) group. Magnification 1:400 for (f)
Qin et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:57 Page 5 of 12noticed a large proportion of necrotic U87MG cells after
same salinomycin stimulation (PI positive and Annexin
V negative, which was largely inhibited by necrosis in-
hibitor Nec-1 (Fig. 2g). More importantly, combination
of Nec-1 and zVADfmk almost completely blocked
salinomycin-induced cytotoxicity in U87MG cell (Fig. 2h).
Together, these results suggest that salinomycin induces
some apoptosis, but mainly necrosis in cultured glioma
cells.
Cyp-D is required for salinomycin-induced necrosis but
not apoptosis in cultured glioma cells
A number of recent studies have shown that the mito-
chondrial protein Cyp-D is required for stresses-induced
necrotic, but not apoptotic cell death [16–19, 23, 31].
Thus, we tested the possible involvement of Cyp-D insalinomycin’s cytotoxicity in glioma cells. Results dem-
onstrated that two Cyp-D inhibitors, sanglifehrin A
(SfA) [32] and cyclosporin A (CSA) [23, 31], significantly
inhibited salinomycin-induced viability reduction in both
U87MG cells (Fig. 3a) and in U251MG cells (Additional
file 1: Figure S2A). Further, siRNA-depleting Cyp-D
(Fig. 3b) also alleviated salinomycin’s cytotoxicity in
U87MG cells (Fig. 3c). Meanwhile, salinomycin-induced
U87MG cell death was also inhibited by SfA, CsA or
Cyp-D depletion (Fig. 3d). These results suggest that
Cyp-D is important for salinomycin-induced cell death
of glioma cells. To further support our hypothesis, we
tested salinomycin’s effect in Cyp-D over-expressing gli-
oma cells. As shown in Fig. 3e, we exogenously intro-
duced wt-Cyp-D in U87MG cells. These cells were
hyper-sensitive to salinomycin, as more cell death were
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Fig. 2 Salinomycin induces both apoptotic and necrotic death of glioma cells. U87MG cells were treated with indicated concentration of
salinomycin (Sali) for 72 h, cell apoptosis was analyzed by Annexin V FACS assay (a) and caspase-3 activity assay (b). The effect of zVADfmk
(60 μM) on salinomycin (Sali, 5 μM)-induced apoptosis was also shown (a-b). The expression of cleaved-caspase-3, cytochrome C and tubulin in
cytosol after indicated salinomycin (Sali) stimulation was tested by Western blotting (c). U87MG cells were pre-treated with an apoptosis inhibitor
zVADfmk (30 or 60 μM) for 1 h, followed by salinomycin (Sali, 5 μM) stimulation, cells were further cultured, MTT assay (d, 72 h) and trypan blue
staining (e, 72 h) were performed. U251MG and EFC-2 glioma cells were treated with salinomycin (Sali, 5 μM) in the presence or absence of
zVADfmk (zVAD, 60 μM) for 72 h, cell death was tested by trypan blue staining assay (f). U87MG cells were pre-treated with a necrosis inhibitor
Nec-1 (25 μM) for 1 h, followed by salinomycin (Sali, 5/10 μM) stimulation, cells were further cultured for 72 h, cell necrosis was analyzed by FACS
(g). The cell viability of U87MG cells with indicated treatment was tested (h). Experiments were repeated four times in this figure, and similar
results were obtained. Error bars indicate SD. *p < 0.05 vs. Ctrl group (a-b). **p < 0.05 vs. Sali group (d-g)
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also noticed some spontaneous cell death in Cyp-D
over-expressing cells (Fig. 3f ). Significantly, salinomycin-
induced cell apoptosis, shown by the Annexin V per-
centage, was not affected by Cyp-D depletion or Cyp-D
over-expression (Fig. 3g), while cell necrosis induced by
salinomycin was inhibited by Cyp-D siRNA, but was ag-
gravated by Cyp-D over-expression (Fig. 3h). Together,
these results indicated that the mitochondrial protein
Cyp-D is required for salinomycin induced necrosis in
cultured glioma cells.
Salinomycin induces Cyp-D and p53 interaction in
mitochondria
Previous studies have shown that Cyp-D-mediated nec-
rotic cell death is through binding with p53 in mito-
chondria [19, 27, 33]. Since we have shown that Cyp-D
is required for salinomycin’s cytotoxicity, we thus testedthe role of p53 in the process. As demonstrated, p53-
shRNA stable knockdown (Fig. 4a) significantly inhibited
salinomycin-induced U87MG cell necrosis, while apop-
tosis was not affected (Fig. 4b). We noticed p53 mito-
chondrial translocation in salinomycin-treated U87MG
cells (Fig. 4c), which formed a complex with the local
protein Cyp-D (Fig. 4d). Similar results were obtained in
U251MG cells (Additional file 1: Figure S2B). The mito-
chondrial complexation between Cyp-D and p53 was
blocked by Cyp-D inhibitor CsA or p53-shRNA deple-
tion (Fig. 4d). Our data suggested that the complexation
was required for mPTP opening, as both CsA and p53
shRNA largely inhibited salinomycin-induced MMP loss
(Fig. 4e). We failed to see p53 phosphorylation at Ser 15
or Ser 20, nor p53 upregulation by salinomycin, while
temozolomide (TMZ) induced p53 phosphorylation and
upregulation (Fig. 4c and f). Based on these data, we
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Fig. 3 Cyp-D is required for salinomycin-induced necrosis but not apoptosis in cultured glioma cells. U87MG cells were pre-treated with the Cyp-D
inhibitor CsA (0.1 μM) or SfA (10 μM) for 1 h, followed by salinomycin (Sali, 5 μM) stimulation, cells were further cultured, MTT assay (a, 72 h) and
trypan blue staining (d, 72 h) were performed. U87MG cells transfected with scramble or Cyp-D siRNA (100 nM each, 48 h) were treated with
salinomycin (Sali, 5 μM) for 72 h, cell viability and death were tested (c and d), expression of Cyp-D and tubulin was shown (b). Stable U87MG
cells with empty vector (p-Super) or Cyp-D-GFP (1 μg/ml each) were treated with salinomycin (Sali, 1 or 5 μM) for 72 h, Cyp-D/tubulin expression (e)
and cell death (f) were tested. Non-transfected control U87MG cells, Cyp-D siRNA-transfected U87MG cells or Cyp-D-over-expressing U87MG cells were
treated with salinomycin (Sali, 5 μM) for 72 h; cell apoptosis (g) and necrosis (h) were tested by FACS. Experiments were repeated three times in this
figure, and similar results were obtained. Error bars indicate SD. *p < 0.05 vs. dmso group (a and d). *p < 0.05 (c and f)
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for mPTP opening and programmed necrosis.
ROS is required for salinomycin-induced necrosis in
cultured glioma cells
Next we tested the possible upstream signal for
salinomycin-induced mPTP opening and necrosis. FACS
results in Fig. 5a showed ROS production by salinomy-
cin in U87MG cells, which are consistent with other
studies [12, 34, 35]. We found that salinomycin de-
creased the activity of SOD in glioma cells, which could
be one reason for ROS increase (Additional file 2: Figure
S1). N-acetyl cysteine (NAC) and pyrrolidinedithiocarba-
mate (PDTC), two well known anti-oxidants inhibited
ROS production by salinomycin. Significantly, both NAC
and PDTC suppressed p53 mitochondrial translocation
(Fig. 5b, input) and following Cyp-D association (Fig. 5b).
Further, salinomycin-induced MMP loss, an indicator
of mPTP opening, was also inhibited by these twoanti-oxidants (Fig. 5c). These results indicate that
salinomycin-induced p53 mitochondrial translocation,
p53-Cyp-D complexation, and the subsequent mPTP
opening might be dependent on ROS production. Based
on these results, we predicted that ROS might also be im-
portant for salinomycin-induced necrosis. As a matter of
fact, salinomycin-induced U87MG cell necrosis was alle-
viated by NAC or PDTC (Fig. 5d), which could explain
that NAC inhibited salinomycin-induced viability loss in
both U251 MG cells and EFC-2 cells (Fig. 5e). Interest-
ingly, using the cells above, ROS results in Fig. 5f showed
that salinomycin-induced ROS was inhibited by Cyp-D
depletion, but was aggravated by Cyp-D over-expression.
Thus, salinomycin-induced mPTP opening might play a
vital role in ROS regulation in glioma cells. To evaluate
the anti-tumor activity of salinomycin in vivo, we gener-
ated subcutaneous xenografts by inoculating the U251
cells to nude mice. Treatment with salinomycin elicited a
marked inhibitory effect on U251 xenograft development
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Fig. 4 Salinomycin induces Cyp-D and p53 interaction in mitochondria. Expression of p53, Cyp-D and tubulin expression in stable U87MG cells
with scramble-shRNA or p53-shRNA was shown (a). Above cell lines were treated with salinomycin (Sali, 5 μM) for 72 h, cell necrosis and apoptosis
were tested by FACS (b). Cultured U87MG glioma cells were treated with indicated concentration of salinomycin (Sali) for 6 h, expression of p53, p-p53
(Ser 15) and Cyp-D in the mitochondrial fraction was tested by Western blots (c). Scramble- or p53- sh-RNA infected U87MG cells, pre-incubated with
CsA (0.1 μM, 1 h), were treated with salinomycin (Sali, 5 μM) for 6 h, mitochondrial association of p53 and Cyp-D was tested (d), expression of above
protein in whole cell lysates (WCL) was shown in input (d), mitochondrial membrane potential was also tested by JC-10 fluorescence assay (e). U87MG
glioma cells were treated with salinomycin (Sali, 5/10 μM), or TMZ (5 mM) for 6 h, p-p53 and regular p53 were tested by Western blots (f). Error bars
indicate SD. Experiments were repeated three times in this figure, and similar results were obtained. *p < 0.05 (b and e)
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inhibited by co-administration with CsA (Fig. 5g). Note
that CsA alone failed to affect U251 growth in vivo
(Fig. 5g). Further, the mice body weight was not signifi-
cantly affected by salinomycin or with CsA, indicating
the relative safety of this regimen (Additional file 3:
Figure S3).
Discussions
A recent study has demonstrated salinomycin to select-
ively kill breast cancer stem cells from tumorspheres
and to inhibit tumor growth in mice [8]. Salinomycin
has been investigated as a possible novel anti-cancer
agent [8, 9]. In the current study, we found that salino-
mycin (0.1–10 μM) decreased the viability of cultured
glioma cells in a concentration- and time-dependent
manner. These results are consistent with previously
published results showing that low concentrations of sal-
inomycin inhibit the survival of many cultured cancercells [9, 11, 34, 36–41]. Interestingly, we found that both
apoptosis and necrosis were induced by cytotoxic salino-
mycin in cultured glioma cells, and necrosis appeared
more important than apoptosis in contributing salino-
mycin’s cytotoxicity.
In the last decades after the discovery of p53, it has be-
come increasingly clear that this protein plays a vital role
in tumor suppression. Previously, it was thought that the
tumor suppressive functions lied solely in p53-mediated
apoptosis, cell cycle arrest, and senescence. However,
more recent research has shown that anti-oncogenic ac-
tivity of p53 can still occur in the absence of these
downstream functions. More specifically, it was recently
found that p53 is also a critical player for cell necrosis.
Upon oxidative stress, p53 triggers mPTP opening by
engaging in a physical interaction with Cyp-D [19],
thereby inducing necrotic cell death in mouse and hu-
man cells. Cells/mice deficiency of Cyp-D or p53 were
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Fig. 5 ROS is required for salinomycin-induced necrosis in cultured glioma cells. U87MG glioma cells were pre-treated with anti-oxidants NAC
(50 μM) or PDTC (25 μM) for 1 h, followed by salinomycin (Sali, 5 μM) stimulation, ROS production was analyzed 3 h after stimulation (a),
mitochondrial expression and association of p53 and Cyp-D were tested at 6 h after stimulation (b), JC-10 green fluorescence intensity was
examined after 6 h (c); cell necrosis was analyzed similarly 72 h after salinomycin stimulation (d). The effect of NAC (50 μM, 1 h pretreatment)
on salinomycin (Sali, 5 μM)-induced viability loss was tested by MTT assay in U251MG and EFC-2 cells (e). Non-transfected control U87MG cells,
Cyp-D siRNA-transfected U87MG cells or Cyp-D-over-expressing U87MG cells were treated with salinomycin (Sali, 5 μM) for 3 h, ROS production
was analyzed (f). (g) U251 cells (1 × 106) were injected subcutaneously into nude mice as described in Materials and Methods, and treatment
was started when the tumors reached 200 mm3. Salinomycin (5.0 mg/kg) and/or CsA (5.0 mg/kg) were administered intraperitoneally once daily
for two weeks. Control mice received vehicle only, according to the same schedule. Tumor volume was measured by caliper with the formula:
π/6 × width 2× length. N = 10 for each group. (h) The proposed signaling pathway of this study. Experiments were repeated three times in this
figure, and similar results were obtained. Error bars indicate SD. * p < 0.05 vs. Sali only group (a, b, d, f and g). # p < 0.05 vs. vehicle group (g)
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studies have demonstrated that this Cyp-D/p53 associ-
ation is also a key player for cancer cell necrosis induced
by some anti-cancer drugs (cisplatin and doxorubicin)
[26, 33], as well as anti-cancer herb medicine (i.e. curcu-
min) [42]. In the current study, we found that Cyp-D-p53
is required for salinomycin-induced necrosis in cultured
glioma cells.
Here, we presented data showing that blockade of
Cyp-D by siRNA-mediated depletion or pharmaco-
logical inhibitors (CsA and SfA) significantly suppressed
salinomycin-induced MMP decrease and glioma cell ne-
crosis. Further, the in vivo anti-tumor activity by salinomy-
cin was also inhibited by CsA. These results suggest that
an inhibitory effect of Cyp-D deficiency on salinomycin-
induced cytotoxicity. On the other hand, Cyp-D overex-
pression facilitated salinomycin-induced glioma cell death.
Thus, we proposed that Cyp-D dependent mPTP opening
should play a vital role in salinomycin-induced cytotoxicity
in glioma cells (Fig. 5h).
In the current study, we found that salinomycin in-
duced p53 mitochondrial translocation without inducing
its phosphorylation (Ser 15 and Ser 20). On the other
hand, TMZ failed to induce p53 mitochondrial trans-
location or Cyp-D association (Data not shown), al-
though it did promote p53 Ser 15 and Ser 20
phosphorylation. Thus, it is suggested that p53 Ser
15 and Ser 20 phosphorylations are not required for
its mitochondrial translocation or Cyp-D complex-
ation by salinomycin. It is possible, though, that other
sites of p53 besides Ser 15 and Ser 20 could be phosphor-
ylated by salinomycin, which might dictate its mito-
chondrial translocation. Salinomycin might also activate
p53 in a phosphorylation-independent manner in gli-
oma cells.
Another major consequence of mPTP formation is in-
creased ROS production/accumulation, leading to re-
lease of oxidative stress from mitochondrial to cytosol.
In the current study, we found that ROS was induced by
salinomycin in glioma cells, which are consistent with
previous findings in other cell lines [12, 34, 35, 41, 43].Meanwhile, ROS appeared important for regulating
mPTP opening through activating of p53, as NAC
and PDTC, two well-known anti-oxidants, inhibited
salinomycin-induced p53 mitochondrial translocation/
Cyp-D association, mPTP opening and glioma cell
death. Thus, ROS is the trigger for the salinomycin-
induced p53-Cyp-D dependent cell necrosis. Interest-
ingly, blockade of Cyp-D by siRNA-mediated depletion
inhibited salinomycin-induced ROS production, while
Cyp-D over-expressing cells showed a higher level of
ROS with salinomycin stimulation. Thus, we propose the
following model: in salinomycin-treated glioma cells,
ROS production triggers p53-Cyp-D mitochondrial
association to open mPTP, leading to secondary ROS
production/accumulation in mitochondria and release
from mitochondrial to cytosol, causing further oxida-
tive damages, and cell necrosis (Fig. 5h).
Conclusions
In conclusion, we found that ROS-p53-Cyp-D dependent
programmed necrosis plays a major role in contributing
salinomycin’s cytotoxicity in cultured glioma cells.
Additional files
Additional file 1: Figure S2. U251MG cells were pre-treated with the
Cyp-D inhibitor CsA (0.1 μM) or SfA (10 μM) for 1 h, followed by salino-
mycin (Sali, 5 μM) stimulation for 72 h, cell viability was tested by MTT
assay (A). U251MG cells were treated with salinomycin (Sali, 5 μM) for 6 h,
mitochondrial association of p53 and Cyp-D was tested (B), expression of
indicated proteins in whole cell lysates (WCL) was shown (B). Experiments
were repeated four times in this figure, and similar results were obtained.
Error bars indicate SD. *p < 0.05.
Additional file 2: Figure S1. U87MG glioma cells were treated with
indicated concentration of salinomycin (Sali) for 3 h, SOD activity was
measured. Experiments were repeated four times in this figure, and
similar results were obtained. Error bars indicate SD. *p < 0.05 vs.
untreated control (“C”) group.
Additional file 3: Figure S3. Weekly body weights of nude mice with
applied treatments described in Fig. 5. Error bars indicate SD.
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